https://www.selleckchem.com/pr....oducts/slf1081851-hy
rategies for brain and/or bone metastatic lung cancer patients. The condition of tumor recurrence and overall death can be worried in the progress of nonmetastatic malignant melanoma (NMMM). Our goal was to construct and validate a prognostic nomogram from a large population database, which is vital for physicians to predict the 3- and 5-year overall survival (OS) rates of patients with NMMM. According to the Surveillance, Epidemiology, and End Results (SEER) program, patients were collected and randomly assigned into t
Like
Comment
Share
